Lung Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_30_3619 - The derived Neutrophil/Lymphocyte Ratio Predicts Poor Clinical Outcome in Early Stage Non-Small Cell Lung Patients Who Received Stereotactic Body Radiation Therapy

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

The derived Neutrophil/Lymphocyte Ratio Predicts Poor Clinical Outcome in Early Stage Non-Small Cell Lung Patients Who Received Stereotactic Body Radiation Therapy
H. Luo1, Y. Cui1, X. Zheng1, and H. Ge2; 1The affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, 2The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

Purpose/Objective(s): Inflammation plays a critical role in carcinogenesis and tumor proliferation. The derived neutrophil-lymphocyte ration (dNLR) is a systemic inflammatory marker. The aim of this study was to evaluate pre-treatment dNLR as prognostic factor in early stage non-small cell lung cancer (NSCLC).

Materials/Methods: Patients with newly diagnosed NSCLC who were eligible for stereotactic body radiotherapy (SBRT) treatment were enrolled from 2011 to 2015 in the study. Pre-treatment dNLR was calculated from peripheral blood count before SBRT. Receiver operating curve (ROC) was applied to determine the optimal cut-off values of dNLR. The impact of pre-treatment dNLR on disease free survival (DFS) and overall survival (OS) was analyzed using Kaplan-Meier curves and Cox proportional models.

Results: In the 64 patients eligible for analysis, median follow up period was 30 months. An optimal cut off value of 2.0 for the dNLR was determined by ROC curves. Kaplan-Meier curves demonstrated that an elevated dNLR was correlated with decreased DFS and OS. In univariate analysis, low dNLR was associated with improved survival; moreover, multivariate analysis revealed that an increased dNLR was an independent significant poor prognostic factor for both DFS and OS.

Conclusion: Pre-treatment dNLR is easily obtained and could be considered as a useful prognostic biomarker in patients with early stage NSCLC that are eligible for SBRT.

Author Disclosure: H. Luo: None. X. Zheng: None. H. Ge: None.

Hui Luo, PhD

Biography:
Name: Hui Luo

Email: dcluohui@sina.com

Phone: 86-18336363627

Fax: 86-0371-65587713

Position: PHD Student

Institution: The Academy of Medical Sciences, Zhengzhou University, The Affiliated Cancer Hospital of Zhengzhou University
Location: Dongming Road 127, Zhengzhou, China


Education: MD, PhD


Specialty & Present Interest: Radiation oncology; Lung cancer; Esophageal cancer.


Representative papers:

[1] Luo H, Peng L, Wang N, Zhang J, Zheng X, Sun Y, et al. Early brain metastasis of advanced gastric cancer with a pathological complete response to neoadjuvant chemotherapy followed by surgery: A case report and literature review. Cancer Biol Ther 2018:1-4.
[2] Luo H, Cui YY, Zhang JG, Sun YN, Zheng XL, Yang CL, et al. Meta-analysis of survival benefit with postoperative chemoradiotherapy in patients of lymph node positive esophageal carcinoma. Clin Transl Oncol 2018;20(7):889-98.
[3] Luo H, Ge H, Cui Y, Zhang J, Fan R, Zheng A, et al. Systemic inflammation biomarkers predict survival in patients of early stage non-small cell lung cancer treated with stereotactic ablative radiotherapy - a single center experience. J Cancer 2018;9(1):182-8.
[4] Chen F, Luo H, Xing L, Liang N, Xie J, Zhang J. Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers. Thorac Cancer 2018;9(1):59-65.

Presentation(s):

Send Email for Hui Luo


Assets

TU_30_3619 - The derived Neutrophil/Lymphocyte Ratio Predicts Poor Clinical Outcome in Early Stage Non-Small Cell Lung Patients Who Received Stereotactic Body Radiation Therapy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for The derived Neutrophil/Lymphocyte Ratio Predicts Poor Clinical Outcome in Early Stage Non-Small Cell Lung Patients Who Received Stereotactic Body Radiation Therapy